Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) patients demonstrating sensitizing oncogenic driver mutations have derived clinical benefit from targeted therapy. EGFR mutations constitutively activate the signaling pathway, leading to prosurvival and antiapoptotic signals. Classic sensitizing EGFR mutations, su...

Descripción completa

Detalles Bibliográficos
Autores principales: Brazel, Danielle, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648093/
https://www.ncbi.nlm.nih.gov/pubmed/34880698
http://dx.doi.org/10.2147/LCTT.S337861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648093/
https://www.ncbi.nlm.nih.gov/pubmed/34880698
http://dx.doi.org/10.2147/LCTT.S337861

Ejemplares similares